lormetazepam

ロルメタゼパム

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/12/27 00:13:27」(JST)

wiki en

[Wiki en表示]

Lormetazepam

Systematic (IUPAC) name
7-chloro-5-(2-chlorophenyl)-3-hydroxy-1-methyl-1H-benzo[e][1,4]diazepin-2(3H)-one
Clinical data
Trade names	Noctamid, Loramet
AHFS/Drugs.com	International Drug Names
Pregnancy category	D
Legal status	DE: Anlage III US: Schedule IV
Routes of administration	Oral
Pharmacokinetic data
Bioavailability	80%
Metabolism	Hepatic
Biological half-life	10–12 hours
Excretion	Renal
Identifiers
CAS Number	848-75-9 N
ATC code	N05CD06
PubChem	CID: 13314
IUPHAR/BPS	7553
ChemSpider	12750 Y
UNII	GU56C842ZA Y
KEGG	D01657 Y
ChEBI	CHEBI:52993 Y
ChEMBL	CHEMBL22097 Y
Synonyms	methyl-lorazepam, N-methyllorazepam
Chemical data
Formula	C16H12Cl2N2O2
Molecular mass	335.2 g/mol
SMILES ClC1=CC=CC=C1C2=NC(C(N(C)C3=C2C=C(C=C3)Cl)=O)O
InChI InChI=1S/C16H12Cl2N2O2/c1-20-13-7-6-9(17)8-11(13)14(19-15(21)16(20)22)10-4-2-3-5-12(10)18/h2-8,15,21H,1H3 Y Key:FJIKWRGCXUCUIG-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

Lormetazepam (INN, or methyl-lorazepam, is a drug which is a short to intermediate acting 3-hydroxy benzodiazepine derivative. It possesses hypnotic, anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties.

Lormetazepam is not approved for sale in the United States or Canada, though it is licensed in the Netherlands as 1 and 2 mg tablets, under the brand names Loramet and Noctamid and as generic, available from several different manufacturers. It is licensed in the UK as 0.5 and 1 mg tablets for short-term treatment (2–4 weeks) of moderately severe insomnia.

The Dutch, British and French system called the System of Objectified Judgement Analysis for assessing whether drugs should be included in drug formularies based on clinical efficacy, adverse effects, pharmacokinetic properties, toxicity and drug interactions was used to assess lormetazepam. A Dutch analysis using the system found that lormetazepam could be suitable to be included in drug prescribing formularies, although zolpidem, zopiclone and temazepam had higher scores and thus can be seen as relatively favorable.

Indications

Lormetazepam is considered a hypnotic benzodiazepine and is officially indicated for moderate to severe insomnia. Lormetazepam is a short-acting benzodiazepine and is sometimes used in patients who have difficulty in maintaining sleep or falling asleep. Hypnotics should only be used on a short-term basis or, in those with chronic insomnia, on an occasional basis.

Side effects

Side effects of lormetazepam are similar to those of other hypnotic benzodiazepines and can for the most part be regarded as a class effect. In a sleep study, 1 mg lormetazepam increased total sleep time, reduced wakefulness, but did not alter REM sleep. However, at 2 mg doses, there were significant increases in stage 3 sleep and reductions in REM sleep. Rebound effects have been reported after chronic use including rebound REM. In one clinical trial with patients who had prior experience with older hypnotics temazepam and nitrazepam, most preferred lormetazepam due to less heavy sedation, amnesia, and residual effects. Some side effects, including drowsiness, amnesia, and respiratory depression, are increased when lormetazepam is combined with other drugs with similar effects e.g. alcohol and nonbenzodiazepine drugs.

Although lormetazepam has been associated with adversely affecting immediate and delayed recall memory functions, studies have shown that lormetazepam's amnesic properties may be lesser compared to other hypnotic benzodiazepines. For example, in a 1984 study comparing the amnesic effects of lormetazepam to temazepam and flurazepam showed that amnesia was smallest after lormetazepam and greatest after temazepam, which had produced greater amnesia than both lormetazepam and flurazepam by a significant margin.

Side effects of lormetazepam include:

• Somnolence
• paradoxical increase in aggression
• lightheadedness
• confusion
• muscle weakness
• ataxia (particularly in the elderly)
• anterograde amnesia
• headache
• vertigo
• hypotension
• salivation changes
• gastro-intestinal disturbances
• visual disturbances
• dysarthria
• tremor
• changes in libido
• incontinence
• urinary retention
• blood disorders and jaundice
• skin reactions
• dependence and withdrawal reactions

Residual 'hangover' effects after nighttime administration of lormetazepam such as sleepiness, impaired psychomotor and cognitive functions may persist into the next day which may impair the ability of users to drive safely and increase risks of falls and hip fractures.

Special precautions

Benzodiazepines require special precaution if used during pregnancy, in children, in alcohol- or drug-dependent individuals and individuals with comorbid psychiatric disorders. Lormetazepam may be unsuitable for the elderly due to residual effects on memory and body sway which may result in falls. Lormetazepam causes impaired driving skills, thus caution is required in individuals who drive or operate machinery.

Tolerance, dependence, and withdrawal

It should be noted that the risks of tolerance, dependence and withdrawal are very low when the drug is used for 2–4 weeks only and that lormetazepam is generally a safe and effective drug when used for no longer than 2–4 weeks. Some sleep disturbance in the form of rebound insomnia can, however, occur even after short-term usage of 7 days. Those with a history of addiction may be at increased risk of problems of tolerance and dependence especially those with a past history of dependency on sedative hypnotic drugs.

Tolerance

Lormetazepam as with other benzodiazepines is generally only recommended for short-term use (2–4 weeks) due to tolerance and loss of efficacy. Tolerance to and loss of the sedative effects of benzodiazepine hypnotics occurs within 14 days of regular use.

Dependence

Dependence is the medical term for addiction. Dependence can either be psychological and/or physical. Psychological dependence can manifest itself as a reliance on a drug to cope with everyday life or in the form of craving. Physical dependence occurs due to physiological adaptations occurring as the body attempts to overcome the drugs effects which is known as tolerance and the continuing need to take the drug to avoid or suppress withdrawal symptoms which can sometimes resemble the original condition being treated. When the dose or the drug is discontinued withdrawal symptoms typically occur. Lormetazepam as with all other benzodiazepines produces both physical and psychological dependence but the main problem of concern is physical dependence which appears in the form of the benzodiazepine withdrawal syndrome after the dosage is reduced or the drug is stopped completely. The dependence induced by lormetazepam is related to changes in the sensitivity of the GABA-BZD receptor complex.

Withdrawal symptoms

Withdrawal symptoms which can occur from stopping benzodiazepines such as lormetazepam can include:

• rebound insomnia and nightmares
• anxiety, panic attacks and agoraphobia
• clinical depression
• malaise
• lack of concentration
• abdominal discomfort
• depersonalisation and feelings of unreality
• emotional lability
• cognitive impairment
• tinnitus
• paraesthesiae, tingling, numbness and pain
• muscle pain, weakness, tension, painful tremor, shaking attacks, jerks, blepharospasm
• excitability, jumpiness and restlessness
• stiffness
• sweats

Abrupt or over rapid withdrawal from high doses can provoke:

• epileptic seizures
• hallucinations (visual, auditory)
• misperceptions

Withdrawal symptoms typically subside after 4–8 weeks but in approximately 10-15% of individuals symptoms can persist for many months and in rare cases years. Some "Withdrawal Symptoms" can emerge despite a constant dosage with the body needing extra dosage in order to feel normal. This is sometimes associated with dosage escalation.

Lormetazepam has a short to intermediate half-life of approximately 10–12 hours. Shorter acting benzodiazepine compounds are generally associated with a more intense and immediate withdrawal reaction compared to longer acting benzodiazepines. For this reason it is generally recommended to cross from lormetazepam to an equivalent dose of diazepam to gradually taper the dosage.

Pharmacology

The bioavailability of lormetazepam was found to be 80%.

Lormetazepam and other benzodiazepine drugs act as positive modulators at the GABA_A benzodiazepine receptor complex. Lormetazepam binds to the benzodiazepine receptor which in turn enhances the effect of the GABA_A receptor producing its therapeutic effects as well as adverse effects. When lormetazepam binds to the benzodiazepine receptor sites in sufficient quantities it produces sedation which is used clinically as a therapeutic treatment for insomnia. Lormetazepam alters the brain electrical activity which has been studied via EEG readings. Lormetazepam appears to be more selective in the type of benzodiazepine receptor it binds to showing a higher affinity for the omega 1 receptor which is responsible for sedation. Changes in EEG can therefore be used to measure the sedative sleep promoting properties of lormetazepam.

Trade names

Noctamid, Ergocalm, Loramet, Dilamet, Sedaben, Stilaze, Nocton, Pronoctan, Noctamide, Loretam, Minias, Aldosomnil

See also

• Benzodiazepine
• Benzodiazepine dependence
• Benzodiazepine withdrawal syndrome
• Long-term effects of benzodiazepines
• Temazepam
• Lorazepam

References

External links

• Inchem.org - Lormetazepam

English Journal

• Licit and illicit drugs in a wastewater treatment plant in Verona, Italy.

• Repice C, Grande MD, Maggi R, Pedrazzani R.SourceDepartment of Mechanical and Industrial Engineering, Faculty of Engineering, University of Brescia, Via Branze, 38, 25123 Brescia, Italy.
• The Science of the total environment.Sci Total Environ.2013 Jun 15;463-464C:27-34. doi: 10.1016/j.scitotenv.2013.05.045. [Epub ahead of print]
• The occurrence of 12 active substances among licit and illicit drugs was investigated over a 2week period inflowing and outflowing in an activated sludge wastewater treatment plant in the city of Verona, Northern Italy. Chemical analyses were performed by means of on-line solid phase extraction coup
• PMID 23777670

• [Trends of use of anxiolytics and hypnotics in Spain from 2000 to 2011].

• Vicente Sánchez MP, Macías Saint-Gerons D, de la Fuente Honrubia C, González Bermejo D, Montero Corominas D, Catalá-López F.SourceDivisión de Farmacoepidemiología y Farmacovigilancia, Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Madrid, España.
• Revista española de salud pública.Rev Esp Salud Publica.2013 Jun;87(3):247-55. doi: 10.4321/S1135-57272013000300004.
• Background: For years, anxiolytics and hypnotics have been one of the most prescribed drug classes in most developed countries. The main aim of this study is to explore the pattern of use of anxiolytic and hypnotic drugs during the period 2000-2011, comparing their growth with that of five european
• PMID 23892676

• A rapid ultrasound-assisted dispersive liquid-liquid microextraction followed by ultra-performance liquid chromatography for the simultaneous determination of seven benzodiazepines in human plasma samples.

• Fernández P, González C, Pena MT, Carro AM, Lorenzo RA.SourceInstitute of Legal Medicine, Forensic Toxicology Service, Faculty of Medicine, 15782 Santiago de Compostela, Spain.
• Analytica chimica acta.Anal Chim Acta.2013 Mar 12;767:88-96. doi: 10.1016/j.aca.2013.01.016. Epub 2013 Jan 17.
• A simple and efficient ultrasound-assisted dispersive liquid-liquid microextraction (UA-DLLME) method has been developed for the determination of seven benzodiazepines (alprazolam, bromazepam, clonazepam, diazepam, lorazepam, lormetazepam and tetrazepam) in human plasma samples. Chloroform and metha
• PMID 23452791

Japanese Journal

• Evaluation of Anxiolytic-like Effects of Some Short-Acting Benzodiazepine Hypnotics in Mice

• , , [他],
• Journal of pharmacological sciences 107(3), 349-354, 2008-07-20
• … Triazolam, brotizolam, rilmazafone, and lormetazepam also showed an anxiolytic-like effect as indicated by the significant increase in the percentage of time spent in the open arms and percentage of the number of open arm entries. …
• NAID 10024321605

• 人格障害を伴った極度の歯科治療恐怖症患者に行ったプロポフォールによる静脈内鎮静法

• 吉田 幸弘,小出 茂代,見崎 徹,小林 雅文,工藤 逸郎
• 日本歯科心身医学会雑誌 13(1), 47-50, 1998
• … She routinely used diazepam, amitriptyline, lormetazepam, and viamin A. …
• NAID 130004307921

• 睡眠導入剤ロルメタゼパム

• 蓮田 麗八郎
• ファルマシア 27(2), 147, 1991-02-01
• NAID 110003659297

Related Links

• ロルメタゼパム(Lormetazepam)に関連する治療薬－処方薬検索 ...

ロルメタゼパム(Lormetazepam)の検索ならお薬検索QLife（キューライフ）。お医者さんが処方する処方薬と、薬局で買える市販薬(OTC)、の効果と副作用、写真、添付文書、保管方法等を掲載。商品名だけでなく一般名や剤形、色などからも ...

• Lormetazepam. Taking Lormetazepam Tablets; insomnia | Patient

A method of treating sleeping disorders and insomnia is through Lormetazepam. Lormetazepam Usually comes in tablet form ... Before taking lormetazepam Some medicines are not suitable for people with certain conditions, and ...

Related Pictures

---

★リンクテーブル★

リンク元

「ロルメタゼパム」

「ロルメタゼパム」

　　[★]

英

lormetazepam

商

エバミール、ロラメット